Tag: securities

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio’s Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company’s common stock with a per share exercise price of $3.03. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

MIDDLETOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Orange County Bancorp, Inc. (the “Company” - Nasdaq: OBT), parent company of Orange Bank & Trust Company, (the “Bank”) and Hudson Valley Investment Advisors, Inc. (“HVIA”), today announced that the underwriters for its recently completed public offering have exercised their overallotment option and completed the sale of an additional 258,064 shares of common stock at the public offering price of $23.25 per share. The expected proceeds to the Company in connection with the exercise of the option and the issuance of the additional shares, after deducting the underwriting discount and commissions but before deducting other expenses payable by the Company, are approximately $5.7 million.

DUBAI, United Arab Emirates, June 09, 2025 (GLOBE NEWSWIRE) -- Micropolis Holding Company (“Micropolis” or the “Company”) (NYSE American: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, today announced that, as previously disclosed in its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which was filed on May 8, 2025 with the Securities and Exchange Commission (the “2024 Annual Report”), the Company’s audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern. See further discussion in Note 3 to the Company’s financial statements included in the 2024 Annual Report. This announcement is made pursuant to NYSE American LLC Company Guide Sections 401(h) and 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company’s financial statements or to its 2024 Annual Report.

MIAMI BEACH, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the launch of an underwritten public offering of 3,160,000 shares of its common stock. The underwriter will also have a 30-day option to purchase up to 474,000 additional shares of common stock. All of the shares of common stock in the offering are being sold by the Company.

SINGAPORE, June 09, 2025 (GLOBE NEWSWIRE) -- JBDI Holdings Limited (“JBDI” or the “Company”) (Nasdaq: JBDI), today announced that it has received notice (the “Notice”) from the Nasdaq Stock Market ("Nasdaq") on June 9, 2025 informing the Company that it has regained compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1), and that the Company was therefore in compliance with the Nasdaq Capital Market’s listing requirements.

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NAPCO Security Technologies, Inc. (NASDAQ: NSSC) between February 5, 2024 and February 3, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.